Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Green Point Science

Israel is one of the early acceptors of medicinal marijuana and researchers have done numerous studies regarding cannabis. A specific look at Moshe Bar to follow.

Facebook GreenPoint Science

GreenPoint Science3 people like this topic

Suggest a Photo
Moshe Bar

Chief Technology OfficerWith over 23 years of experience in the seed industry (since 2007), Moshe served as global crop leader for pepper and as global head of scouting and strategic projects at Syngenta. During this time at Syngenta Moshe gain his experience working in a global senior management positions as a team member of Vegetable R&D leadership team. Prior to joining Syngenta, Moshe served as a Tomato breeder and VP R&D at Zeraim Gedera, a leading Israeli vegetable seed company, where he gained his first experience in plant breeding and management. Moshe brings in-depth knowledge in plant breeding, biotechnology.Golden Leaf Holdings is taking the lead on product innovation and application of best practices and new technology to the cannabis industry. We're leveraging science and research to explore and develop new proprietary strains and growing techniques that support health and wellness. Moshe Bar, Chief Technology Officer, Green Point Science

Current Medical Marijuana Research From Golden Leaf Holdings Website

Below is a sampling of recent research on medical marijuana that provides an overview of therapeutic effects as related to various ailments.

Epilepsy Diabetes Mellitus Dystonia Alzheimer's Disease Chronic Pain FibromyalgiaHepatitis C Gastrointestinal Disorders Rheumatoid Arthritis Post-Traumatic StressParkinson's Disease Multiple Sclerosis Pruritus Human Immunodeficiency Virus (HIV)Gliomas/Cancer Osteoporosis

I didn't see any of the research on these samples to be from Greenpoint Science. Also, limited portion of his career has been devoted to cannabis beginning only in 2015 and also he seems to be time splitting with Biotagate. This division has been shut down as part of cost cutting initiatives, the company stating they would seek to find similar research closer to home.

Company Overview of Golden Leaf Holdings, Inc.Key Executives for Golden Leaf Holdings

Name

Board Relationships

Title

Age

Donald M. Robinson

13 Relationships

Chief Executive Officer and Director

--

Brian Scott Gentry

No Relationships

Chief Financial Officer

--

Andy Richard Hartogh

5 Relationships

Director and President of Greenpoint Oregon Inc

--

Moshe Bar

No Relationships

Chief Technology Officer

--

Golden Leaf Holdings, Inc. Board Members*

Name

Board Relationships

Primary Company

Age

Karl Risk Miller Jr.

18 Relationships

Avamere Family of Companies Inc.

--

Donald M. Robinson

13 Relationships

Golden Leaf Holdings, Inc.

--

Andy Richard Hartogh

5 Relationships

Golden Leaf Holdings, Inc.

--

Philip Van Den Berg

5 Relationships

Golden Leaf Holdings, Inc.

--

Elijah Cohl

5 Relationships

Golden Leaf Holdings, Inc.

--

Golden Leaf Holdings, Inc. CEO Compensation Industry Average

Moshe Bar Moshe Bar

Founder and Managing Director at Biotagate

Current
  1. Biotagate,
  2. Green Point Science
Previous
  1. Syngenta Seeds,
  2. Zeraim Gedera
Education
  1. The Hebrew Universit

Background

Founder and Managing DirectorBiotagateApril 2015 - Present (10 months)Israel

CEOGreen Point ScienceJanuary 2015 - Present (1 year 1 month)Rehovot,Israel

Head of scouting, collaboration and strategic project vegetabalesSyngenta SeedsFebruary 2012 - December 2014 (2 years 11 months)

Head of strategic project vegetabalesSyngenta SeedsJanuary 2011 - January 2012 (1 year 1 month)

Global pepper R&D leadSyngenta SeedsJune 2008 - January 2011 (2 years 8 months)

VP R&DZeraim GederaJune 2004 - June 2008 (4 years 1 month)

Education

The Hebrew UniversityThe Hebrew UniversityDoctor of Philosophy (NYSE:PHD), Biotechnology1991 - 1996

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Additional disclosure: Feel free to discuss